Jose-Maria Raya
Overview
Explore the profile of Jose-Maria Raya including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
96
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pastor-Galan I, Pereira A, Arellano-Rodrigo E, Martin I, Mosquera-Orgueira A, Gomez-Casares M, et al.
Leukemia
. 2024 Aug;
38(11):2483-2486.
PMID: 39215061
No abstract available.
2.
Mosquera-Orgueira A, Arellano-Rodrigo E, Garrote M, Martin I, Perez-Encinas M, Gomez-Casares M, et al.
Hemasphere
. 2024 Mar;
8(3):e60.
PMID: 38510992
No abstract available.
3.
Hernandez-Sanchez A, Villaverde-Ramiro A, Arellano-Rodrigo E, Garrote M, Martin I, Mosquera-Orgueira A, et al.
Am J Hematol
. 2024 Jan;
99(4):755-758.
PMID: 38291566
Prognostic impact of non-MPN driver gene mutations in primary myelofibrosis. MIPSS70: Mutation-Enhanced International Prognostic Score System.
4.
Mosquera-Orgueira A, Perez-Encinas M, Hernandez-Sanchez A, Gonzalez-Martinez T, Arellano-Rodrigo E, Martinez-Elicegui J, et al.
Hemasphere
. 2022 Dec;
7(1):e818.
PMID: 36570691
Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) with heterogeneous clinical course. Allogeneic hematopoietic cell transplantation remains the only curative therapy, but its morbidity and mortality require careful candidate selection. Therefore,...
5.
Hernandez-Boluda J, Pastor-Galan I, Arellano-Rodrigo E, Raya J, Perez-Encinas M, Ayala R, et al.
Br J Haematol
. 2022 Sep;
199(4):529-538.
PMID: 36089912
Available data have proved insufficient to develop consensus recommendations on the prevention of thrombosis and bleeding in myelofibrosis (MF). We evaluated the incidence and risk factors of vascular complications in...
6.
Alvarez-Larran A, Garrote M, Ferrer-Marin F, Perez-Encinas M, Mata-Vazquez M, Bellosillo B, et al.
Cancer
. 2022 Apr;
128(13):2441-2448.
PMID: 35417564
Background: Ruxolitinib is approved for patients with polycythemia vera (PV) who are resistant/intolerant to hydroxyurea, but its impact on preventing thrombosis or disease-progression is unknown. Methods: A retrospective, real-world analysis...
7.
Hernandez-Boluda J, Pereira A, Kroger N, Cornelissen J, Finke J, Beelen D, et al.
Am J Hematol
. 2021 Jun;
96(10):1186-1194.
PMID: 34152630
Allogeneic hematopoietic cell transplantation (allo-HCT) is increasingly used in older myelofibrosis (MF) patients, but its risk/benefit ratio compared to non-transplant approaches has not been evaluated in this population. We analyzed...
8.
Hernandez-Boluda J, Pereira A, Correa J, Alvarez-Larran A, Ferrer-Marin F, Raya J, et al.
Ann Hematol
. 2018 Feb;
97(5):813-820.
PMID: 29396714
Prognostic models are widely used in clinical practice for transplant decision-making in myelofibrosis (MF). We have compared the performance of the International Prognostic Scoring System (IPSS), dynamic IPSS (DIPSS), and...
9.
Hernandez-Boluda J, Correa J, Alvarez-Larran A, Ferrer-Marin F, Raya J, Martinez-Lopez J, et al.
Br J Haematol
. 2017 Apr;
181(3):397-400.
PMID: 28419426
No abstract available.
10.
Hernandez-Boluda J, Correa J, Garcia-Delgado R, Martinez-Lopez J, Alvarez-Larran A, Fox M, et al.
Eur J Haematol
. 2016 Dec;
98(4):407-414.
PMID: 28009442
Objective: Erythropoiesis-stimulating agents (ESAs) are commonly used to treat the anemia of myelofibrosis (MF), but information on the predictors of response is limited. Methods: Results of ESA therapy were analyzed...